Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.

Leukemia research - 1 Jul 2018

Lancman Guido, Brunner Andrew, Hoffman Ronald, Mascarenhas John, Hobbs Gabriela

Abstract excerpt

We retrospectively reviewed treatment outcomes for 57 patients with myeloproliferative neoplasms in blast phase (MPN-BP). The median overall survival (OS) of the entire cohort was 5.8 months. For patients receiving induction therapy, 67% achieved a complete response (CR) and 75% received stem cell transplantation (SCT). Median OS for all transplanted patients (n = 19) was not reached after a median follow-up of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blast Crisis

Share to Chromosome Aberrations

Share to Disease Management

Share to Myeloproliferative Disorders

Share to Stem Cell Transplantation

Share to Transplantation, Homologous

Source

Identifiers

PMID: 29807273
DOI: 10.1016/j.leukres.2018.05.004

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.PMID 29807273Read ↗

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.Semantic proximity Read ↗

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Accelerated and blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomesSemantic proximity Read ↗

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Accelerated and Blast Phase Myeloproliferative Neoplasms.Semantic proximity Read ↗

Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.Semantic proximity Read ↗

Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.Semantic proximity Read ↗

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.